A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)

Trial Profile

A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2017

At a glance

  • Drugs Nintedanib (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms INJOURNEY
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 21 Apr 2017 This trial has been completed in the Netherlands.
    • 25 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top